454 Life Sciences and Roche Diagnostics to merge in $155m deal
This article was originally published in Clinica
Executive Summary
454 Life Sciences, the Branford, Connecticutt DNA-sequencing technology developer, is to be fully integrated into Roche Diagnostics, according to a definitive merger agreement announced today.